NRX Pharmaceuticals Inc is trading at $3.55 (23% down) in pre-market sessions after announcing a proposed underwritten public offering of common stock.
- The company stated on June 2, 2026, that the offering size and terms are not yet finalized.
- The plan to issue new shares has triggered investor concerns regarding potential equity dilution, putting significant downward pressure on the stock.